We are live on
!
Find out more
SCM
Silverarc Capital Management Portfolio holdings
AUM
$980M
1-Year Est. Return
470.8%
This Fund
S&P 500
This Quarter
Est. Return
+2.41%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$242M
AUM Growth
-$107M
(-31%)
Cap. Flow
-$82.3M
Cap. Flow
% of AUM
-33.98%
Top 10 Holdings %
Top 10 Hldgs %
35.16%
Holding
111
New
21
Increased
25
Reduced
24
Closed
39
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
MRUS
Merus
MRUS
|
+$6.87M |
| 2 |
ETNB
89bio
ETNB
|
+$5.71M |
| 3 |
KALV
KalVista Pharmaceuticals
KALV
|
+$5.4M |
| 4 |
Cogent Biosciences
COGT
|
+$5.12M |
| 5 |
Karyopharm Therapeutics
KPTI
|
+$5.07M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Madrigal Pharmaceuticals
MDGL
|
+$10.9M |
| 2 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
+$10.4M |
| 3 |
Immunovant
IMVT
|
+$9.22M |
| 4 |
Xenon Pharmaceuticals
XENE
|
+$5.8M |
| 5 |
BLU
BELLUS Health Inc.
BLU
|
+$5.49M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 87.87% |
| 2 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Phathom Pharmaceuticals
PHAT
$708M
| $1.43M | 0.59% |
+200,000
| New | +$1.76M |
|
52
Intellia Therapeutics
NTLA
$1.49B
| $1.41M | 0.58% |
37,858
+5,088
| +16% | +$200K |
|
|
CLYM
53
Climb Bio
CLYM
$681M
| $1.41M | 0.58% |
485,955
+76,753
| +19% | +$264K |
|
54
Seres Therapeutics
MCRB
$46.8M
| $1.32M | 0.54% |
11,626
-7,095
| -38% | -$767K |
|
55
Sarepta Therapeutics
SRPT
$1.57B
| $1.28M | 0.53% |
+9,270
| New | +$1.2M |
|
|
ATXS
56
DELISTED
Astria Therapeutics
ATXS
| $1.25M | 0.52% |
93,823
+12,619
| +16% | +$171K |
|
57
Cue Biopharma
CUE
$113M
| $1.09M | 0.45% |
10,209
| – | – |
|
|
ALLK
58
DELISTED
Allakos
ALLK
| $939K | 0.39% |
211,010
-269,691
| -56% | -$1.72M |
|
59
Viridian Therapeutics
VRDN
$2.09B
| $926K | 0.38% |
36,381
+33,381
| +1,113% | +$1.07M |
|
60
Jasper Therapeutics
JSPR
$21M
| $905K | 0.37% |
+50,000
| New | +$924K |
|
61
BridgeBio Pharma
BBIO
$15.7B
| $663K | 0.27% |
+40,000
| New | +$466K |
|
62
Acumen Pharmaceuticals
ABOS
$155M
| $597K | 0.25% |
146,922
-148,193
| -50% | -$774K |
|
|
IMGN
63
DELISTED
Immunogen Inc
IMGN
| $576K | 0.24% |
150,000
-257,269
| -63% | -$1.1M |
|
64
TELA Bio
TELA
$32.7M
| $576K | 0.24% |
+54,096
| New | +$597K |
|
65
Aligos Therapeutics
ALGS
$26.2M
| $552K | 0.23% |
+25,275
| New | +$966K |
|
66
CVRx
CVRX
$137M
| $280K | 0.12% |
30,000
-284,584
| -90% | -$3.76M |
|
67
Monte Rosa Therapeutics
GLUE
$1.4B
| $243K | 0.1% |
+31,156
| New | +$217K |
|
|
LVTX
68
DELISTED
LAVA Therapeutics
LVTX
| $233K | 0.1% |
140,291
-297,471
| -68% | -$833K |
|
69
Compugen
CGEN
$222M
| $232K | 0.1% |
330,188
-337,255
| -51% | -$277K |
|
|
ELOX
70
DELISTED
Eloxx Pharmaceuticals, Inc. Common Stock
ELOX
| $136K | 0.06% |
54,075
+27,199
| +101% | +$98.4K |
|
71
Rocket Pharmaceuticals Warrant
RCKTW
$149K
| $11.5K | ﹤0.01% |
+104,828
| New | +$20.2K |
|
|
FRTX
72
DELISTED
Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
| $6.6K | ﹤0.01% |
10,000
| – | – |
|
|
AKRO
73
CALL
DELISTED
Akero Therapeutics
AKRO
| – | – |
-150,000
| Closed | -$8.22M |
|
|
AKRO
74
PUT
DELISTED
Akero Therapeutics
AKRO
| – | – |
-150,000
| Closed | -$8.22M |
|
75
Altimmune
ALT
$552M
| – | – |
-50,546
| Closed | -$601K |
|
Similar funds
BIP
MVM
MFWP
FCM
KL
GFP
ADIC
PCM
Silverarc Capital Management's Q1 2023 Portfolio in Review
As of Q1 2023, Silverarc Capital Management held 111 positions worth $242M, down 31% from $350M the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Silverarc Capital Management withdrew a net $82.3M in Q1 2023, closing 39 positions and reducing 24 holdings. Its most notable exit was Immunovant, an estimated $9.22M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 80% a quarter earlier, followed by Technology.
Against the trend, Silverarc Capital Management opened a new position in 89bio worth $6.67M.
- Silverarc Capital Management's largest Q1 2023 buy was 89bio: 438,215 shares worth $6.67M.
- Silverarc Capital Management added most to Merus in Q1 2023, an estimated $6.87M increase.
- Silverarc Capital Management's biggest Q1 2023 reduction was Madrigal Pharmaceuticals, cutting an estimated $10.9M.
- Silverarc Capital Management fully exited Immunovant in Q1 2023, selling an estimated $9.22M.
- Silverarc Capital Management's ten largest holdings make up 35% of its $242M portfolio in Q1 2023.
- Silverarc Capital Management opened 21 new positions and closed 39 in Q1 2023.
- Silverarc Capital Management's portfolio value fell 31% quarter-over-quarter to $242M.
Based on Silverarc Capital Management's 13F filing for Q1 2023, filed 15 May 2023.